We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

Bruker Corporation

Company price
60.39 USD -2.02 ( 3.24%)
Last update at 2026-11-12T15:43:00Z
VOLUME
275028
Market Cap
6102.63M

Momentum Score

…

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools; innovative nuclear magnetic resonance (NMR) and electron paramagnetic resonance (EPR) products; solutions for in-vivo processes and drug discovery; aftermarket solutions; solutions for lab automation and digitalization; mass spectrometry solution and test kits, DNA test strips, and fluorescence-based PCR technologies; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; services for transcriptional profiling and multiomic analysis; superconducting materials, such as metallic low temperature superconductors; multifilament round and rectangular LTS wires in both monolithic and wire-in-channel formats; designs and manufactures Cuponal; metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation was founded in 1960 and is headquartered in Billerica, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
58.67
Low
60.87
High
52 Week Price Range
28.41
Low
56.14
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Bruker Corporation makes scientific instruments and analytical solutions for life sciences, materials research and diagnostics. Long-term growth could be driven by rising R&D in drug discovery, proteomics and genomics, expanding clinical diagnostics, and service and consumables recurring revenue. The diversified product lineup across research and applied markets appears positioned to offer steady demand exposure.
Principal risks include sensitivity to capital-equipment spending cycles, intense competitive and technological pressures, acquisition integration challenges, and supply-chain or currency volatility.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
62.41
Dividend Yield
0.49%
Revenue TTM
3436.50M
Revenue Per Share
22.64
Gross Profit TTM
1647.90M
Debt / Equity
0.83
ROE
-0.38%
Net Debt
1744.10M
ROCE
1.35%
Diluted EPS TTM
-0.15

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 21.00M 205.20M 546.20M 413.90M 393.60M
Minority interest -0.30M -0.70M -3.10M -1.90M -3.50M
Net income -8.60M 113.10M 427.20M 296.60M 277.10M
Selling general administrative 946.50M 893.80M 730.00M 610.80M 564.50M
Selling and marketing expenses - - 0.60M -3.40M -3.30M
Gross profit 1567.50M 1649.50M 1513.30M 1305.70M 1209.60M
Reconciled depreciation 220.30M 183.80M 102.10M 88.00M 89.10M
Ebit 67.20M 254.80M 560.60M 432.70M 413.30M
Ebitda 287.50M 438.60M 675.50M 550.40M 516.70M
Depreciation and amortization 220.30M 183.80M 114.90M 117.70M 103.40M
Non operating income net other - - - -18.80M -19.70M
Operating income 216.60M 253.10M 436.90M 432.70M 413.30M
Other operating expenses 3219.90M 3113.30M 2527.60M 2068.30M 1990.30M
Interest expense 46.20M 47.90M 16.40M 16.10M 14.30M
Tax provision 29.30M 91.40M 104.00M 116.40M 113.00M
Interest income 14.80M 9.30M 7.70M 4.10M 0.90M
Net interest income -46.70M -38.60M -6.40M -18.80M -19.70M
Income tax expense 29.30M 91.40M 117.70M 116.40M 113.00M
Total revenue 3436.50M 3366.40M 2964.50M 2530.70M 2417.90M
Total operating expenses 1350.90M 1396.40M 1076.40M 843.30M 782.00M
Cost of revenue 1869.00M 1716.90M 1451.20M 1225.00M 1208.30M
Total other income expense net -195.60M -47.90M 109.30M -18.80M -19.70M
Net income from continuing ops -8.30M 113.80M 322.20M 298.50M 280.60M
Net income applicable to common shares - - - 296.60M 277.10M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 6241.40M 5806.70M 4249.90M 3618.50M 3650.00M
Intangible assets 899.60M 912.50M 330.50M 270.90M 211.80M
Other current assets 83.10M 100.80M 85.80M 202.60M 176.60M
Total liab 3731.10M 3991.50M 2836.60M 2486.70M 2565.20M
Total stockholder equity 2456.50M 1781.20M 1377.20M 1125.70M 1084.60M
Deferred long term liab - - - 62.30M 46.00M
Other current liab 570.20M 401.90M 454.90M 487.10M 481.20M
Common stock 1.80M 1.80M 1.70M 1.70M 1.70M
Capital stock 1.80M 1.80M 1.70M 1.70M 1.70M
Retained earnings 2361.80M 2406.70M 2323.80M 1926.00M 1659.50M
Other liab - - - 318.20M 404.90M
Good will 1547.70M 1507.30M 582.60M 457.60M 339.50M
Other assets - 0.00M - 208.90M 160.90M
Cash 298.80M 183.40M 488.30M 645.50M 1068.20M
Total current liabilities 1279.20M 1281.30M 1202.10M 913.80M 938.50M
Current deferred revenue 441.30M 438.20M 400.00M 225.70M 197.50M
Net debt 1744.10M 2061.90M 891.30M 573.70M 266.00M
Short term debt 51.80M 64.60M 144.50M 18.70M 112.40M
Short long term debt 16.60M 32.50M 121.20M 18.70M 112.40M
Short long term debt total 2042.90M 2245.30M 1379.60M 1219.20M 1334.20M
Other stockholder equity 172.40M -523.80M -954.30M -816.80M -568.40M
Property plant equipment - - - 487.00M 406.10M
Total current assets 2212.50M 2053.20M 2164.20M 2124.50M 2471.80M
Net tangible assets - - - 1210.90M 312.50M
Short term investments - - 12.00M 100.00M 100.00M
Net receivables 736.00M 701.20M 621.80M 472.70M 416.90M
Long term debt 1852.50M 2061.80M 1160.30M 1200.50M 1221.80M
Inventory 1094.60M 1067.80M 968.30M 803.70M 710.10M
Accounts payable 215.90M 234.10M 202.70M 182.30M 147.40M
Noncontrolling interest in consolidated entity - - - 11.90M 14.10M
Accumulated other comprehensive income -79.50M -103.50M 6.00M 14.80M -8.20M
Common stock total equity - - - 1.70M 1.70M
Retained earnings total equity - - - 1926.00M 1659.50M
Treasury stock - - - -1085.00M -820.30M
Non currrent assets other 241.10M 232.70M 175.70M -76.80M 70.80M
Non current assets total 4028.90M 3753.50M 2085.70M 1494.00M 1178.20M
Capital lease obligations 173.80M 151.00M 98.10M 51.20M 59.70M
Long term debt total - - - 1200.50M 1221.80M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -7.20M -1757.30M -438.50M -239.30M -50.30M
Change to liabilities - - - 30.80M 100.60M
Total cashflows from investing activities -196.50M -1757.30M - -251.60M -192.40M
Net borrowings -491.30M 875.90M - 0.30M 489.60M
Total cash from financing activities 135.10M 1229.80M -193.40M -415.20M 318.70M
Change to operating activities - - - 2.60M -19.20M
Net income 29.20M 113.80M 427.20M 298.50M 280.60M
Change in cash 116.40M -304.90M -157.20M -423.00M 386.20M
Begin period cash flow 186.70M 491.60M 645.50M 1071.70M 685.50M
End period cash flow 303.10M 186.70M 488.30M 648.70M 1071.70M
Total cash from operating activities 134.10M 251.30M 350.10M 262.00M 282.40M
Issuance of capital stock 677.60M 403.00M 6.80M 2.80M 7.00M
Depreciation 220.30M 183.80M 114.90M 88.00M 89.10M
Other cashflows from investing activities -31.80M 1.10M - -168.40M 10.00M
Dividends paid 22.80M 30.20M 29.40M 29.80M 24.20M
Change to inventory 12.10M -69.80M -125.00M -140.10M -67.00M
Change to account receivables 54.20M -40.60M -0.90M -67.90M -95.30M
Sale purchase of stock -10.00M 0.00M -152.30M -263.10M -153.30M
Other cashflows from financing activities -10.50M -18.90M 0.30M -14.10M 492.40M
Change to netincome - - - 12.90M 41.40M
Capital expenditures 90.80M 115.30M 106.90M 119.00M 92.00M
Change receivables - - - -67.90M -95.30M
Cash flows other operating - - - 49.20M 26.20M
Cash and cash equivalents changes - - - -392.50M 408.70M
Change in working capital -144.60M -78.20M -87.80M -143.50M -125.20M
Stock based compensation 20.20M 25.30M 24.00M 27.70M 17.20M
Other non cash items 133.70M 70.40M -103.80M 8.10M 26.50M
Free cash flow 43.30M 136.00M 243.20M 143.00M 190.40M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
BRKR
Bruker Corporation
-2.02
3.24%
60.39 - 15.22 1.78 2.48 2.28 25.93
ABT
Abbott Laboratories
-0.71
0.65%
108.58 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC
0.28
0.28%
101.89 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation
-2.16
0.68%
316.63 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG
-
-%
47.31 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

Bruker Corporation

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools; innovative nuclear magnetic resonance (NMR) and electron paramagnetic resonance (EPR) products; solutions for in-vivo processes and drug discovery; aftermarket solutions; solutions for lab automation and digitalization; mass spectrometry solution and test kits, DNA test strips, and fluorescence-based PCR technologies; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; services for transcriptional profiling and multiomic analysis; superconducting materials, such as metallic low temperature superconductors; multifilament round and rectangular LTS wires in both monolithic and wire-in-channel formats; designs and manufactures Cuponal; metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation was founded in 1960 and is headquartered in Billerica, Massachusetts.

40 Manning Road, Billerica, MA, United States, 01821

978 663 3660

11085

Name Title Year Born
Dr. Frank H. Laukien Ph.D. Chairman, CEO & Pres 1960
Mr. Gerald N. Herman Exec. VP & CFO 1958
Dr. Mark R. Munch Ph.D. Corp. Exec. VP and Pres of Bruker Nano Group & Corp. 1962
Mr. Juergen Srega Pres of Bruker CALID Group & Bruker Daltonics Division 1955
Dr. Falko Busse Ph.D. Pres of Bruker BioSpin Group 1967
Mr. Justin Joseph Ward Sr. Director of Investor Relations & Corp. Devel. NA
Mr. J. Brent Alldredge J.D. Gen. Counsel 1975
Mr. Collin J. D'Silva Pres of Chemical Analysis Division 1957
Stacey Desrochers Treasurer & Director of Investor Relations NA
Mr. Urban Faeh Pres of Bruker Optics Division & Managing Director of Bruker Optik GmbH NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…